Welcome to Cellula BioPharma
Cellula BioPharma is developing a game changing CAR-T platform technology for solid tumors.
Our CAR-T technology
CAR T cell therapy has represented an exciting breakthrough in the treatment of patients with hematologic malignancies leading to the FDA approval of six CAR-T products.
To date, >200 registered CAR T cell clinical trails against solid tumor showed that the antitumor activity of CAR-T in solid tumors is very disappointing.
We have developed a game changing CAR T cell therapy platform suitable for solid tumors
Our team is comprised of experienced serial entrepreneurs, investigators, and physicians with the necessary VC, GMP, and clinical resources. "
Development of MR-CAR T cell therapy
Differentiation 1: INO is superior to current cytokine strategies for promoting T cell persistence
Differentiation 2: MR-CAR-T is superior to ADO blockers to overcome ADO-mediated immunosuppression